Skip to main content

Advertisement

SpringerLink
Log in

Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients

MMPs in tear samples from type 1 diabetes

  • Basic Science
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

The presence of matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetes mellitus (DM) patients and potential correlations with clinical parameters (Schirmer testing, glycosylated hemoglobin-HBA1C) were investigated.

Methods

Tear samples from the right eyes of 27 type 1 DM patients and 17 healthy control subjects were included in this study. The MMP gelatinolytic activity was determined by gelatin zymography analysis using sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE), while MMP and TIMP concentrations (in ng/ml) were quantified in tears of type 1 diabetic patients and healthy controls, with the use of enzyme-linked immunosorbent assay (ELISA).

Results

MMP-9, TIMP-1, -2 levels, MMP-9/TIMP-1, and MMP-9/TIMP-2 ratios in the patient group were significantly elevated. There was a significant correlation between TIMP-2 and HBA1C values, as well as between MMP-2 and MMP-9.

Conclusions

Significant correlations between TIMP-2 and HBA1C and between Schirmer test results and HBA1C were revealed. Significant increase in tear MMP and TIMP levels in pediatric type 1 diabetic patients may be suggestive of disease progression and localized pathologic remodelling. Further studies are required in order to ascertain whether MMPs and TIMPs could be employed as indicators of early disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schultz RO, Van Horn DL, Peters MA, Klewin KM, Schutten WH (1981) Diabetic keratopathy. Trans Am Ophthalmol Soc 79:180–199

    PubMed  CAS  Google Scholar 

  2. Schultz RO, Matsuda M, Yee RW, Edelhauser HF, Schultz KJ (1984) Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol 98:401–410

    Article  PubMed  CAS  Google Scholar 

  3. Friend J, Thoft RA (1984) The diabetic cornea. Int Ophthalmol Clin 24:111–123

    Article  PubMed  CAS  Google Scholar 

  4. Herse PR (1988) A review of manifestations of diabetes mellitus in the anterior eye and cornea. Am J Optom Physiol Opt 65:224–230

    Article  PubMed  CAS  Google Scholar 

  5. Liu J, Shi B, He S, Yao X, Willcox MD, Zhao Z (2010) Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Mol Vis 16:2931–2938

    PubMed  CAS  Google Scholar 

  6. Nepp J, Abela C, Polzer I, Derbolav A, Wedrich A (2000) Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca? Cornea 19:487–491

    Article  PubMed  CAS  Google Scholar 

  7. Sethi CS, Bailey TA, Luthert PJ, Chong NH (2000) Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 84:654–666

    Article  PubMed  CAS  Google Scholar 

  8. Sivak JM, Fini E (2002) MMPs in the eye: emerging roles for matrix metallo-proteinases in ocular pathology. Prog Retin Eye Res 21:1–14

    Article  PubMed  CAS  Google Scholar 

  9. Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H (2004) Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 145:620–626

    Article  PubMed  CAS  Google Scholar 

  10. Borden P, Heller RA (1997) Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Euk Gene Exp 7:159–178

    Article  CAS  Google Scholar 

  11. Clark IM, Swingler TE, Sampieri CL, Edwards DR (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–1378

    Article  PubMed  CAS  Google Scholar 

  12. Mäkitalo L, Kolho KL, Karikoski R, Anthoni H, Saarialho-Kere U (2010) Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol 45:862–871

    Article  PubMed  Google Scholar 

  13. Musiał K, Zwolińska D (2011) Matrix metalloproteinases (MMP-2, -9) and their tissue inhibitors (TIMP-1, 2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones 16:97–103

    Article  PubMed  Google Scholar 

  14. Papakonstantinou E, Dionyssopoulos A, Aletras AJ, Pesintzaki C, Minas A, Karakiulakis G (2004) Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis. J Am Acad Dermatol 51:526–533

    Article  PubMed  Google Scholar 

  15. Senzaki H (2006) The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child 91:847–851

    Article  PubMed  CAS  Google Scholar 

  16. Boden G, Song W, Pashko L, Kresge K (2008) In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. Diabetes 57:476–483

    Article  PubMed  CAS  Google Scholar 

  17. Derosa G, D’Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, Penno G, Del Prato S, Paniga S, Cicero AF (2007) Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 33:129–134

    Article  PubMed  CAS  Google Scholar 

  18. Yang C, Zhu P, Yan L, Chen L, Meng R, Lao G (2009) Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. J Am Pediatr Med Assoc 99:489–496

    Google Scholar 

  19. Acera A, Rocha G, Vecino E, Durán JA (2008) Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res 40:315–321

    Article  PubMed  CAS  Google Scholar 

  20. Lema I, Sobrino T, Durán JA, Díez-Feijoo E (2009) Subclinical keratoconus and inflammatory molecules from tears. Br J Ophthalmol 93:820–824

    Article  PubMed  CAS  Google Scholar 

  21. Rohini G, Murugeswari P, Prajna NV, Lalitha P, Muthukkaruppan V (2007) Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis. Cornea 26:207–211

    Article  PubMed  Google Scholar 

  22. Gunczler P, Lanes R, Soros A, Verdu L, Ramon Y, Guevara B, Beer N (2006) Coronary artery calcification, serum lipids, lipoproteins, and peripheral inflammatory markers in adolescents and young adults with type 1 diabetes. J Pediatr 149:320–323

    Article  PubMed  CAS  Google Scholar 

  23. Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z (2007) Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 20:444–452

    PubMed  CAS  Google Scholar 

  24. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL (2007) Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 30:2321–2326

    Article  PubMed  CAS  Google Scholar 

  25. Thrailkill KM, Bunn RC, Fowlkes JL (2009) Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 35:1–10

    Article  PubMed  CAS  Google Scholar 

  26. American Diabetes Association(2009) Executive summary: standards of medical care in diabetes—2009. Diabetes Care 32:S6–S12

    Article  Google Scholar 

  27. Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E (2011) Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol 89:339–345

    Article  PubMed  CAS  Google Scholar 

  28. Death AK, Fisher EJ, McGrath KC, Yue DK (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263–269

    Article  PubMed  CAS  Google Scholar 

  29. Pugliese G, Pricci F, Pugliese F, Mene P, Lenti L, Andreani D, Galli G, Casini A, Bianchi S, Rotella CM (1994) Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 43:478–490

    Article  PubMed  CAS  Google Scholar 

  30. Goebbels M (2000) Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol 84:19–21

    Article  PubMed  CAS  Google Scholar 

  31. Grus FH, Sabuncuo P, Dick HB, Augustin AJ, Pfeiffer N (2002) Changes in the tear proteins of diabetic patients. BMC Ophthalmol 2:4

    Article  PubMed  CAS  Google Scholar 

  32. Derosa G, Avanzini MA, Geroldi D, Fogari R, Lorini R, De Silvestri A, Tinelli C, Rondini G, d’Annunzio G (2005) Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 70:119–125

    Article  PubMed  CAS  Google Scholar 

  33. Parshley DE, Bradley JMB, Samples JR, Van Buskirk EM, Acott TS (1995) Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res 14:537–544

    Article  PubMed  CAS  Google Scholar 

  34. Manaviat MR, Rashidi M, Afkhami-Ardekani M, Shoja MR (2008) Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol 8:10

    Article  PubMed  Google Scholar 

  35. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

    Article  Google Scholar 

  36. Thrailkill KM, Moreau CS, Cockrell GE, Jo CH, Bunn RC, Morales-Pozzo AE, Lumpkin CK, Fowlkes JL (2010) Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 37:336–343

    Article  PubMed  CAS  Google Scholar 

  37. Akinci A, Cetinkaya E, Aycan Z (2007) Dry eye syndrome in diabetic children. Eur J Ophthalmol 17:873–878

    PubMed  CAS  Google Scholar 

  38. Maxwell PR, Timms PM, Chandran S, Gordon D (2001) Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18:777–780

    Article  PubMed  CAS  Google Scholar 

  39. Teles RM, Teles RB, Amadeu TP, Moura DF, Mendonça-Lima L, Ferreira H, Santos IM, Nery JA, Sarno EN, Sampaio EP (2010) High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions. Infect Immun 78:1012–1021

    Article  PubMed  CAS  Google Scholar 

  40. Gerlach RF, Tanus-Santos JE (2005) Circulating matrix metalloproteinase-9 levels as a biomarker of disease. Clin Cancer Res 11:8887

    Article  PubMed  CAS  Google Scholar 

  41. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158–5166

    Article  PubMed  CAS  Google Scholar 

  42. Robak E, Wierzbowska A, Chmiela M, Kulczycka L, Sysa-Jedrejowska A, Robak T (2006) Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediators Inflamm 2006:17898

    Article  PubMed  Google Scholar 

  43. Tuuttila A, Morgunova E, Bergmann U, Lindqvist Y, Maskos K, Fernandez-Catalan C, Bode W, Tryggvason K, Schneider G (1998) Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution. J Mol Biol 284:1133–1140

    Article  PubMed  CAS  Google Scholar 

Download references

Declarations

The authors wish to declare that there is no conflict of interest in this manuscript, and that there are no funding sources to declare.

Author information

Authors and Affiliations

  1. 2nd Department of Ophthalmology, School of Medicine, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki Ring Road, Thessaloniki, 564 03, Macedonia, Greece

    Chrysanthos Symeonidis, Ioannis Tsinopoulos, Asimina Mataftsi & Stavros A. Dimitrakos

  2. 2nd Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece

    Eleni Papakonstantinou

  3. 4th Department of Paediatrics, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Macedonia, Greece

    Asimina Galli

  4. 1st Department of Paediatrics, School of Medicine, Aristotle University of Thessaloniki, Hippokrateion General Hospital, Thessaloniki, Macedonia, Greece

    Spyridon Batzios

Authors
  1. Chrysanthos Symeonidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleni Papakonstantinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asimina Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ioannis Tsinopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Asimina Mataftsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Spyridon Batzios
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stavros A. Dimitrakos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chrysanthos Symeonidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Symeonidis, C., Papakonstantinou, E., Galli, A. et al. Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients. Graefes Arch Clin Exp Ophthalmol 251, 741–749 (2013). https://doi.org/10.1007/s00417-012-2221-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-012-2221-3

Keywords

Search

Navigation